Treatment of type 2 diabetes mellitus

被引：35

作者：

Feinglos, MN

Bethel, MA

机构：

[1] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Div Endocrinol & Metab, Durham, NC 27710 USA

来源：

MEDICAL CLINICS OF NORTH AMERICA | 1998年 / 82卷 / 04期

关键词：

D O I：

10.1016/S0025-7125(05)70023-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although most patients with type 2 diabetes mellitus can be initially managed with diet and exercise alone, most eventually require at least oral agents if not insulin to maintain glycemic control. Appropriate therapeutic regimens may be difficult to design, given the diversity of drugs available for clinical use. Physicians must consider not only glycemic control, but also patient preference, concomitant medical conditions, and cost when designing therapeutic regimens.

引用

页码：757 / +

页数：36

共 122 条

[41] Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes [J].

Feinglos, MN ;

Thacker, CH ;

English, J ;

Bethel, MA ;

Lane, JD .

DIABETES CARE, 1997, 20 (10) :1539-1542

[42]

Fertig BJ, 1995, DIABETES AM, P519

[43] Diet and exercise in type 2 diabetes mellitus [J].

Feuerstein, BL ;

Weinstock, RS .

NUTRITION, 1997, 13 (02) :95-99

[44]

Froesch ER, 1996, DIABETES METAB REV, V12, P195, DOI 10.1002/(SICI)1099-0895(199610)12:3<195::AID-DMR164>3.0.CO

[45]

2-G

[46]

GERICH JE, 1989, NEW ENGL J MED, V321, P1231

[47] Cardiac and glycemic benefits of troglitazone treatment in NIDDM [J].

Ghazzi, MN ;

Perez, JE ;

Autonucci, TK ;

Driscoll, JH ;

Huang, SM ;

Faja, BW ;

Whitcomb, RW .

DIABETES, 1997, 46 (03) :433-439

[48] METFORMIN FOR OBESE, INSULIN-TREATED DIABETIC-PATIENTS - IMPROVEMENT IN GLYCEMIC CONTROL AND REDUCTION OF METABOLIC RISK-FACTORS [J].

GIUGLIANO, D ;

QUATRARO, A ;

CONSOLI, G ;

MINEI, A ;

CERIELLO, A ;

DEROSA, N ;

DONOFRIO, F .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (02) :107-112

[49] A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents [J].

Goldberg, RB ;

Holvey, SM ;

Schneider, J ;

Bansal, S ;

Blonde, L ;

Boden, G ;

Bransome, ED ;

Clark, C ;

Clarke, D ;

Davis, M ;

Davis, S ;

Gerich, J ;

Goldberg, R ;

Haag, B ;

Hendler, R ;

Josse, RG ;

JovanovicPeterson, L ;

Karam, JH ;

Kennedy, F ;

Kilo, C ;

Klachko, D ;

Knopf, RF ;

Kolterman, O ;

Krosnick, A ;

Leiter, LA ;

Leslie, C ;

Malone, JK ;

Meenan, A ;

Metzger, B ;

Morrison, AD ;

Raskin, P ;

Reeves, M ;

Rendell, M ;

Saudek, C ;

Schwartz, S ;

Skor, D ;

Tung, PC .

DIABETES CARE, 1996, 19 (08) :849-856

[50] The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes [J].

Grant, PJ .

DIABETES CARE, 1996, 19 (01) :64-66

← 1 2 3 4 5 6 7 8 9 10 →